ARDELYX, INC. Stock, NASDAQ:ARDX
34175 ARDENWOOD BLVD., FREMONT, CA 94555
United States of America
Number of Employees: 86
Ardelyx, Inc. develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the United States. Its lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. The company is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications. Its drug candidates in the stages of research and development include RDX013 for the treatment of patients with hyperkalemia; RDX011 for the discovery and development of second-generation NHE3 inhibitors; and RDX023 for the discovery and development of gut-biased FXR agonists for the treatment of GI and inflammatory diseases. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.